A collection of movers and shakers who have changed position recently in the laboratory sector, part one of a new series of reports
Scientific Laboratory Supplies (SLS), a supplier of laboratory equipment and consumables, reports two key appointments to its senior management team.
Geoff Douglas is appointed marketing manager and brings SLS the benefit of his extensive sales and marketing experience in global manufacturing and distribution.
His previous experience includes positions with companies such as Camlab and Whatman International.
Richard Scott, formerly of Barlowworld Scientific, is appointed trade sales manager, and brings SLS important experience in the management of trade and re-selling accounts.
The British Safety Council (BSC) has announced the appointment of Brian Nimick as chief executive.
"Brian brings a wealth of experience in strategy, business, organisational development and health and safety to the BSC" explains Nina Wrightson, chairman of BSC, "and this experience complements our long term strategy to help everyone achieve a healthy, safe and sustainable lifestyle".
In 2001, Nimick became director general of the Confederation of Passenger Transport, the trade organisation representing the interests of the road passenger transport industry.
He was also a key member of an EU sponsored committee looking at safety and security on public transport.
The European Science Foundation announced Professor Marja Makarow will succeed John Marks to be its chief executive, making her the first woman to take the top post in the science organisation's 33-year history.
Over the past decade Makarow, who is an active scientist in the field of molecular cell biology, has been in positions of trust serving a number of national and intergovernmental research funding and research performing organisations in Europe.
Leading sample management software provider Titian Software has created a US subsidiary and appointed Michael Girardi as its president.
Titian specialises in sample management software for the life science industry and its Mosaic software suite is already in use in six of the world's top 20 bio-pharma companies.
Prior to joining Titian, Girardi has held senior management and leadership positions with Tecan (RTP, North Carolina), Remp (Oberdiessbach, Switzerland) and Zymark (Hopkinton, Massachusetts) and earned his MBA from Boston College's Carroll School of Management.
Molecular Profiles has announced the appointment of Rob Whittock as associate director of materials characterisation.
Based in Nottingham, he will provide technical direction and leadership to the materials characterisation team and support independent experts across the UK, Europe and USA; and clients' scientific staff, patent attorneys and in-house patent counsel.
Whittock holds a PhD in physical organic chemistry and previously worked as a senior scientist at AstraZeneca, where he gained a wealth of experience in pharmaceutical R+D, particularly in solid state characterisation (polymorphism).
Upfront Chromatography announced the appointment of Karsten Lindved as chief financial officer (CFO) .
Lindved joins Upfront from Dan Net/Mach where he was chief financial officer.
BioTek Instruments reports that John Fiducia has accepted the position of director of global service operations.
Fiducia will be responsible for supporting all of BioTek's customers and distribution partners in areas including service, technical support and technical training".
He has over 20 years of wide ranging service experience in laboratory instrumentation and diagnostics, having spent 16 years with Abbott Laboratories.
Meanwhile, Briar Alpert, president and CEO of BioTek Instruments, has been elected to the board of directors of the Analytical and Life Science Systems Association (Alssa) after unanimous vote of the current board members.
Alssa, located in Alexandria, VA, is the primary US trade association for manufacturers and marketers of products and technology (including instrumentation, chemical reagents, consumables and software) used for analysis and measurement in the life sciences and chemistry.
XStream Systems announced the addition of Alan Clock as senior vice president of sales and marketing.
Clock joins XStream with wealth of experience, having held senior sales executive and national account roles for AmerisourceBergen, McKesson, Cardinal Health and ActiveHealth Management.
Flextraction has appointed Andrew Seaton based in Bangor, Co Down, as sales manager for the whole of Ireland.
Seaton has been appointed to set up Flextraction's marketing, sales and after sales requirements covering the multi-million pound market for fume and dust extraction equipment in Ireland.
He was previously area sales manager for Donaldson Filtration (GB), where he re-vitalised the company's activities in the Irish market establishing a network of re-sellers and obtaining a considerable number of large orders.
ClinPhone announces the appointment of Jason Liew as associate director of business development for Scandinavia, demonstrating the company's commitment to the expansion of its Scandinavian business.
Liew has been recruited to develop existing partnerships and also establish relationships with new customers in the region.
The Scandiavian region is home to a large concentration of pharmaceutical and biotechnology companies.
Agendia has appointed six members to its clinical and scientific advisory board.
The newly established board is comprised of internationally-recognised scientists with research and clinical expertise.
The advisors review early research programmes and provide critical evaluations from academic and clinical perspectives.
Agendia welcomes: Piet Borst (chair), Jose Baselga, Matt van de Rijn, David Kerr, Kent Osborne, and Joe Gray to its board.
"The addition of these six distinguished scientists and clinicians will enable us to further strengthen strategies in cancer and other diseases" said Bernhard Sixt, chief executive officer at Agendia.
In similar vein, Molecular Profiles has announced the expansion of its scientific panel with the appointment of industry guru Professor Lisbeth Illum.
The scientific panel complements the intellectual property, patent litigation support and contract research services already offered by Molecular Profiles to the pharmaceutical and biomedical industries.
The panel originally consisted of Molecular Profiles's founders from the School of Pharmacy at the University of Nottingham, Professors Martyn Davies, Saul Tendler, Clive Roberts and Philip Williams.
Illum has over 25 years' experience in the pharmaceutical industry, and has held a variety of academic, editorial and professional positions including consulting to several multinational pharmaceutical companies.
Lab21 has announced the appointment of Graham Mullis as its new CEO.
Mullis has held executive positions at FTSE and Nasdaq listed medical device companies including 1-800 Contacts and Biocompatibles International and pharmaceutical roles at Hoechst Roussel and R P Scherer.
He joins Lab21 from Optivue, a company formed to develop and license pharmaceutical and medical device applications in optical products, where he is a co-founder.
Cancer Research Technology (CRT), the specialist oncology development and commercialisation company, has recruited Hamish Ryder as its first director of discovery.
Ryder has more than 20 years experience in the pharmaceutical and biotechnology sectors, most recently as director of drug discovery at Almirall.
He will lead operations at CRT's development laboratories and oversee the continuing expansion of the staff and facilities.
Molecular Partners has announced the appointment of Jorn Aldag, president and CEO of Evotec, as president to the board.
Powder characterisation company Freeman Technology has appointed Jon Yin as application specialist for the United States - the company's first direct appointment in the US market.
Managing director Reg Freeman confirmed that the move will enable Freeman Technology to further develop applications and technical support for its growing customer base in the United States".
Gentronix has announced the appointment of Steven Beasley as commercial director and member of the board.
Beasley joins Gentronix with over 20 years experience of the pharmaceutical and biotechnology industry gained from both research and commercial roles.
Previously CEO of bioscience knowledge organisation Bioknex and chief business officer of De Novo Pharmaceuticals , Beasley will head the commercial operations of Gentronix as it moves forward with its growth plans for GreenScreen HC and its next generation products.
